Data completeness
2/8 — Basic
TRILAFON (perphenazine) by Merck & Co. is clinical pharmacology pharmacokinetics following oral administration of perphenazine tablets, mean peak plasma perphenazine concentrations were observed between 1 to 3 hours.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRILAFON (perphenazine) is an oral syrup antipsychotic medication belonging to the phenothiazine class. It works by blocking dopamine receptors in the central nervous system to treat psychotic disorders. The drug is characterized by extensive hepatic metabolism via CYP2D6, with significant pharmacokinetic variability based on individual metabolizer status.
Pre-Launch
Pre-launch stage suggests active build-out of commercial infrastructure with expanding team needs across marketing, sales, and medical affairs functions.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacokinetics Following oral administration of perphenazine tablets, mean peak plasma perphenazine concentrations were observed between 1 to 3 hours. The plasma elimination half-life of perphenazine was independent of dose and ranged between 9 and 12 hours. In a study in…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer
Started May 2007
Healthy
Worked on TRILAFON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.